ukcitymedia.co.uk latest news from uk stockmarket - forum
Home Page
 Register Register
Log in Log in



The Forum is CLOSED

For new registrants. Current contributors continue to post.



 

ukcitymedia.co.uk Forum Index - Share Club -Postings for UK investment related issues


Tepnel Life Sciences plc (TED-AIM) - Reply to topic

> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Tue Apr 08, 2008 9:16 am   Reply with quote      



Whilst looking around the market for a company to invest in I came across Tepnel Life the AIM Heath Care. Pharmaceuticals and biotechnology company. Market Cap 21.29m. I licked the look of the company so I brought some shares, my investment is based on the true fact that the company has just issued a strong set of Preliminary Results,

As I see it the company share price should trade up over the next few weeks, I am upbeat about the prospects of TED and am more than pleased to find this small cap with prospects in these uncertain times, follow the story at club website. 5 www.shareclubuk.co.uk



> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Tue Apr 15, 2008 9:51 am   Reply with quote      



True information taken from the Preliminary results for the year ended 31 December 2007

Highlights
Substantial underlying organic growth leading to the first year of significant profitability and operating cash inflows
Revenue increased by 19% to 17.8m (2006: 15.0m) and by 22% on a constant currency basis
Operating profit increased to 1.39m (2006: 0.05m)
Earnings before interest, tax, depreciation and amortization (EBITDA) increased by 192% to 2.01m (2006: 0.69m)
First significant operating cash inflow reported at 1.72m (2006: 0.12m)
Improvement in gross margin to 57% (2006: 54%)
Increase in earnings per share to 0.59p (2006: 0.06p)
Strong sales growth in the Molecular Diagnostics division driven by the LifeMatch range of products
Major investment in the future of the Research Products and Services division with the completion of the new pharmaceutical facility in Livingston, Scotland and newly launched service lines

(TED share price is holding it own at this time, no head in the sand, no make-believe just good old fashion share trading with the company as it stands today. 5.



> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Tue Apr 22, 2008 10:50 am   Reply with quote      



The news on the block is that Tepnel Life Sciences share price is trading at a discounted price of 8.50p giving an opportunity to make profits TED is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities. The most recent news from the company is that AXA S.A. now hold 27,732,428 voting right shares (16.27%.) of the issued shares. //



> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Tue Apr 29, 2008 10:39 am   Reply with quote      



Tepnel Life Sciences (TED) is a UK-based international life sciences products and services group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Target markets are pharmaceutical, biotechnology, healthcare, hospitals, academic/research institutes, food manufacturers and regulatory authorities.

The most recent news from the company is that AXA S.A. now hold 27,732,428 voting right shares (16.27%.) of the issued shares capital or Investment of AXA S.A. gives a strong influence to Buy shares with TED the comfort factor.

The news from the market place is that Tepnel Life Sciences share price is trading at a discounted price of 9.00p giving an opportunity to make profits from the share price. Market Cap is £21.01mlion. //.



> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Tue May 06, 2008 11:04 am   Reply with quote      



Positive news Tepnel preferred supplier agreement with AstraZeneca for DNA extraction services is extended. Share price responds by trading up. Now I understand why AXA S. A , Holds 27,732,428 shares in the company.



> happydays


Joined: 05 Aug 2006
Posts: 212

View user's profile








Post Mon May 12, 2008 1:17 pm   Reply with quote      



As a matter of interest I have had a telephone conversation with my contact at Tepnel Life. He informed me that the company was very pleased with business at the present time, TEDís agreement with AstraZenca interacted a major step in the companyís marketing, only to be enhanced by the news that TED has signed a two year global distribution agreement with world's largest online supplier of antibodies, Abcam.

At the end of our telephone conversation I felt that the company is now well in line to take on new clints and extra business for their life sciences products. I look forward to the next announcement from the company, I will now increase my stock holdings in the company. /



> alankeys


Joined: 05 Aug 2006
Posts: 176

View user's profile








Post Thu Jul 31, 2008 10:43 am   Reply with quote      



TEPNEL LIFE SCIENCES PLC ANNOUNCES INTERIM RESULTS FOR THE

6 MONTHS ENDED 30 JUNE 2008

Substantial increase in revenues and profits




Manchester, UK, Stamford, USA, 31 July 2008: Tepnel Life Sciences plc (AIM: TED), the international Molecular Diagnostics and Research Products and Services Group, announces interim results for the 6 month period ended 30 June 2008.




'Tepnel continues to deliver very strong revenue and operating profit growth across its entire business. Our new purpose built, state-of-the-art pharmaceutical services facility, along with our recently launched Biopharmaceutical and Genotyping services, have been a great success with strong customer demand.

Additionally, Tepnel's immunological products are showing good growth and have now begun to penetrate worldwide markets. Tepnel's Molecular Diagnostics division also continues to exhibit strong growth led by our LifeMatch range of products and our Elucigene CF and QST*R genetic tests' stated Ben Matzilevich, Tepnel's Chief Executive Officer. 'We believe Tepnel is very well positioned for future growth bolstered by a growing menu of novel molecular diagnostic products and demand for our advanced pharmaceutical outsourcing services. Our strong H1 performance and positive outlook are testament to the loyalty, commitment and dedication of Tepnel's staff and shareholders alike.'




2008 Highlights




Revenue increased to £11.8m from £8.8m, an increase of 34% compared to the prior period and 29% on a constant currency basis

Gross profit increased 34% to £6.9m compared to £5.1m in 2007

An increase of 149% in operating profit to £1.5m from £0.6m in 2007

EBITDA increased 118% to £1.9m from £0.9m in 2007

Operating cash inflow increased to £1.5m from a cash outflow of £0.2m in 2007

Tepnel continues to deliver significant and sustained growth in both revenue and operating profit across both divisions in line with its strategic and operational plans:

Research Products and Services revenue increased by 28% driven by the strong demand for its pharmaceutical outsourcing services from its new state-of-the-art facility in Livingston and newly introduced Biopharmaceutical and Genotyping service lines

Molecular Diagnostics revenue increased by 39% driven by the Transplant Diagnostics business line. The LifeMatch range of products continued to show strong growth compared to the prior period




Chairman's Statement



Overview


The first six months of 2008 has been another extremely successful period for Tepnel as the Group continues to deliver significant revenue and operating profit growth. Revenue grew by 34% to £11.8m and operating profit for the 6 month period was £1.5m.


Significant growth has been delivered across both divisions and the performance continues to demonstrate the success of Tepnel's corporate strategy to build leadership positions in niche markets in the Molecular Diagnostics and Research Products and Services sectors. The key financial highlights are as follows:


Revenue for the 6 months ended 30 June 2008 increased to £11.8m from £8.8m, an increase of 34% on the prior period and 29% on a constant currency basis

Operating profit increased by 149% to £1.5m from £0.6m in 2007

EBITDA increased by 118% to £1.9m from £0.9m in 2007

Operating cash inflow increased to £1.5m compared to an operating cash outflow of £0.2m for 2007

Basic earnings per share for the period were 0.60 pence compared to 0.27 pence in 2007




Research Products and Services



Tepnel's Research Products and Services division has had an excellent first half of 2008, delivering revenue growth of 28% (25% on a constant currency basis) to £4.9m. This division provides outsourcing services for the pharmaceutical, biotechnology and healthcare industries, food safety products and immunological reagents.



This growth has been primarily driven by the demand for Tepnel's pharmaceutical outsourcing services from its state-of-the-art pharmaceutical facility based in Livingston, Scotland. In March 2008, the Group announced the completion of Phase II of the construction, which completed the facility, and marked the launch of its biopharmaceutical and clinical genotyping services.


The introduction of these new services gives Tepnel access to two rapidly growing market sectors, enabling the Group to offer an expanded service menu to new and existing customers. In addition, these new services simultaneously enhance the product development capabilities of our Molecular Diagnostics division whilst positioning us to become one of UK's leading service providers.


The Research Products and Services division continues to gain business from some of the largest pharmaceutical companies in the world. In May 2008, the Group extended its preferred supplier agreement with AstraZeneca for DNA extraction services. The Group's reputation for client service and technical expertise has been key to the delivery of new pharmaceutical outsourcing contracts.


The Group's immunological reagent line has delivered good growth in both direct sales in the UK, US and France, and through our distributor network. In May 2008, the Group announced a two year extension to its global licensing agreement with Abcam, the world's largest on-line supplier of antibody products. This agreement covers the worldwide distribution of Tepnel's Diaclone range of diagnostic and research products and includes a guaranteed annual minimum in sales, stren
gthening Tepnel's global reach to customers in both academia and industry.


Molecular Diagnostics



Tepnel's Molecular Diagnostics division also had a very strong first half of 2008, delivering revenue growth of 39% (32% on a constant currency basis) to £6.8m. This division focuses on the organ transplant monitoring, foetal diagnostic testing and genetic predisposition testing markets. Tepnel's innovative product range includes the LifeMatch transplant monitoring assays and the Elucigene genetic predisposition assays.


The LifeMatch range of products continues to gain market share and increased sales through new customers and a broadening product range. Tepnel continues to develop innovative new product lines using the Luminex xMAP technology providing a strong base for future growth of the LifeMatch range.


Sales of Tepnel's QST*R product for the rapid detection during pregnancy of common genetic abnormalities, has shown strong growth compared to the prior year and continues to gain momentum throughout Europe.


Tepnel is continuously expanding its product pipeline of molecular diagnostic products and technologies and in June 2008 announced that the Group had been awarded a BBSRC grant to develop new technologies for molecular diagnostic applications. Tepnel is developing a technology for the rapid detection and identification of pathogenic micro-organisms which can cause potentially fatal infections in human and animals. The research project enables Tepnel to explore this innovative technology and assess its potential for human and animal applications.


Future Prospects


These excellent interim results for the first 6 months of 2008 once again demonstrate Tepnel's continued progress in achieving sustainable growth in both revenues and operating profits and are testament to the loyalty, commitment and dedication of Tepnel's staff and shareholders alike.


The Group is strategically focused on delivering growth across both divisions. The Molecular Diagnostics division is focused on key growth markets, principally organ transplant monitoring and foetal distress diagnostics, and developing products which utilise its technologies for new markets, including the blood bank market. The Research Products and Services division, through its new pharmaceutical facility and recently launched services is well placed to access the growing Biopharmaceutical and Genotyping markets.


The significant investment made in Tepnel's new facilities and its new products and services development, means the Group is well placed for future growth.



> alankeys


Joined: 05 Aug 2006
Posts: 176

View user's profile








Post Sun Jan 25, 2009 7:48 pm   Reply with quote      



7:41 am, January 23, 2009
Barclays added to Tepnel stake prior to bid approach


Barclays Plc increased its stake in Tepnel Life Sciences Plc, at least two days before the company received a bid approach, it emerged this morning.

Tepnel (AIM: TED), said in a stock exchange announcement that it was informed on Tuesday that Barclays Plc had increased its holding to 11 million shares, or 5 per cent, following a new purchase.

Yesterday, the Wythenshawe-based molecular diagnostics company said it had received an approach which may or may not lead to a takeover offer.

Tepnel stock jumped 23 per cent after the announcement about a possible bid but were unchanged at 14.25p when the market opened this morning.

Tepnelís shares had already risen 9 per cent in the past week after gaining 50 per cent during 2008 on the back of growing demand for the companyís diagnostic testing kits.

It recently received an order from the Illinois Department of Public Health for its Elucigene CF-US cystic fibrosis test and it hopes other states will follow suit.

http://www.crainsmanchesterbusiness.co.uk/apps/pbcs.dll/article?AID=/20090123/FREE/901239997/1015



ukcitymedia.co.uk Forum Index - Share Club -Postings for UK investment related issues - Tepnel Life Sciences plc (TED-AIM) - Reply to topic

 



FAQ FAQ     Search Search     Register Register     Profile Profile     Log in Log in







All rights reserved    ukcitymedia stock market trading buleetin board    © Site Terms and Conditions apply. Based in London. UK